Treatment of retinoblastoma vitreous base seeding

Ophthalmology. 1998 Jan;105(1):120-4. doi: 10.1016/s0161-6420(98)91617-7.

Abstract

Objective: The purpose of the study is to describe results of a new treatment for retinoblastoma vitreous base seeding.

Design: The study design was a retrospective review of patients treated at an ocular oncology referral center.

Participants: Five eyes of five patients with vitreous base seeding that occurred after previous external beam radiation therapy were treated between October 1987 and December 1994.

Intervention: A customized plaque made from iridium-192/platinum wire was placed to deliver 4000 cGy to the tumor apex along its entire length and systemic chemotherapy (consisting of carboplatin, vincristine, and etoposide) was given.

Main outcome measures: Eye preservation and tumor control were measured.

Results: Vitreous base seeding was controlled completely and the eye preserved in four of the five treated eyes with an average follow-up of 26.2 months.

Conclusions: The combination of a customized iridium-192 plaque and systemic chemotherapy is an effective means of treating vitreous base seeding of retinoblastoma.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Brachytherapy*
  • Carboplatin / administration & dosage
  • Combined Modality Therapy
  • Etoposide / administration & dosage
  • Female
  • Humans
  • Infant
  • Iridium Radioisotopes / therapeutic use*
  • Male
  • Neoplasm Seeding*
  • Retinal Neoplasms / pathology
  • Retinal Neoplasms / therapy*
  • Retinoblastoma / pathology
  • Retinoblastoma / therapy*
  • Retrospective Studies
  • Treatment Outcome
  • Vincristine / administration & dosage
  • Vitreous Body* / drug effects
  • Vitreous Body* / pathology
  • Vitreous Body* / radiation effects

Substances

  • Iridium Radioisotopes
  • Vincristine
  • Etoposide
  • Carboplatin